Inventor · disambiguated record
Kyle D. Konze
Also filed as: KONZE KYLE · KONZE KYLE D
17 granted patents·9 pending applications·58 citations·filing 2018–2025
92Inventor score
Files withMORPHIC THERAPEUTIC INC18ONO PHARMACEUTICAL CO4SCHROEDINGER INC2HARRISON BRYCE A1RELAY THERAPEUTICS INC1
Top patents by PatentIndex Score
26 records- 0196US12145935B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2023·Granted Nov 19, 2024·4 cites·20 claims
- 0296US11795167B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Oct 24, 2023·5 cites·19 claims
- 0395US11827621B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Nov 28, 2023·5 cites·9 claims
- 0494US12415796B2Inhibitors of (αv)(β6) integrinMORPHIC THERAPEUTIC INC·Filed 2023·Granted Sep 16, 2025·2 cites·8 claims
- 0594US11739087B2Inhibiting (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Aug 29, 2023·5 cites·9 claims
- 0694US11046669B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2019·Granted Jun 29, 2021·8 cites·35 claims
- 0793US11046685B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2018·Granted Jun 29, 2021·8 cites·42 claims
- 0893US11040955B2Inhibitors of (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2018·Granted Jun 22, 2021·8 cites·59 claims
- 0993US10759756B2Antagonists of human integrin α4β7MORPHIC THERAPEUTIC INC·Filed 2019·Granted Sep 1, 2020·7 cites·42 claims
- 1091US11691968B2Compound having KDM5 inhibitory activity and pharmaceutical use thereofONO PHARMACEUTICAL CO·Filed 2022·Granted Jul 4, 2023·2 cites·3 claims
- 1189US11370773B1Inhibiting human integrin (alpha-4) (beta-7)MORPHIC THERAPEUTIC INC·Filed 2021·Granted Jun 28, 2022·2 cites·24 claims
- 1285US12459942B2Inhibiting (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2024·Granted Nov 4, 2025·0 cites·18 claims
- 1385US12221416B2Antagonists of human integrin α4β7MORPHIC THERAPEUTIC INC·Filed 2023·Granted Feb 11, 2025·0 cites·20 claims
- 1484US2025223289A1Inhibitors of (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 1583US11174228B2Antagonists of human integrin (α4)(β7)MORPHIC THERAPEUTIC INC·Filed 2020·Granted Nov 16, 2021·1 cites·20 claims
- 1681US11104661B1Inhibiting human integrin (α-4) (β-7)MORPHIC THERAPEUTIC INC·Filed 2020·Granted Aug 31, 2021·1 cites·24 claims
- 1781US2023317214A1Methods for predicting an active set of compounds having alternative cores, and drug discovery methods involving the sameSCHROEDINGER INC·Filed 2023·Application pending·0 cites
- 1879US12269817B2Compound having KDM5 inhibitory activity and pharmaceutical use thereofONO PHARMACEUTICAL CO·Filed 2023·Granted Apr 8, 2025·0 cites·3 claims
- 1972US2022340529A1Antagonists of human integrin (alpha4)(beta7)MORPHIC THERAPEUTIC INC·Filed 2021·Application pending·0 cites
- 2068US2025214984A1Compound having kdm5 inhibitory activity and pharmaceutical use thereofONO PHARMACEUTICAL CO·Filed 2025·Application pending·0 cites
- 2168US2020071322A1Inhibiting (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2019·Application pending·0 cites
- 2267US2020354359A1Inhibiting (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2020·Application pending·0 cites
- 2355US11710543B2Methods for predicting an active set of compounds having alternative cores, and drug discovery methods involving the sameSCHROEDINGER INC·Filed 2018·Granted Jul 25, 2023·0 cites·9 claims
- 2451US2023219949A1Inhibitors of (alpha-v)(beta-6) integrinHARRISON BRYCE A·Filed 2022·Application pending·0 cites
- 2549US2020392161A1Shp2 phosphatase inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2648US2022289751A1Compound having kdm5 inhibitory activity and pharmaceutical use thereofONO PHARMACEUTICAL CO·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kyle D. Konze files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →